Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus POHERDY.
HC #1 vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Renal: 90% as unchanged drug; fecal: 10%.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid